๐Ÿš€ Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. ๐Ÿ”ฅ
Login

News on Medial

Healthians posts Rs 263 Cr revenue in FY25; nears breakeven

EntrackrEntrackr ยท 16h ago
Healthians posts Rs 263 Cr revenue in FY25; nears breakeven
Medial

Healthians posts Rs 263 Cr revenue in FY25; nears breakeven Healthians didn't manage notable growth in the fiscal year ending March 2025. However, the WestBridge-backed company narrowed its losses by 89% year on year and neared break-even during the same period. The firmโ€™s operating revenue increased 8% year-on-year to Rs 263 crore in FY25, up from Rs 243 crore in FY24, as per its consolidated financial statements filed with the Registrar of Companies (RoC). Including non-operating income of Rs 7 crore, the companyโ€™s total income grew 7% to Rs 270 crore during the year. Cost optimisation played a key role in supporting the companyโ€™s financial recovery. Total expenses declined 8% to Rs 275 crore in FY25, compared to Rs 298 crore last year. Among the major cost heads, employee benefits, the largest expense category, dropped 13% year-on-year to Rs 104 crore in FY25 from Rs 120 crore in FY24. Cost of materials contracted 7% to Rs 54 crore. Advertising costs rose 10% to Rs 43 crore. Meanwhile, depreciation and finance costs remained stable at Rs 29 crore and Rs 15 crore, respectively. The improvement in revenue and control of key expenses helped Healthians bring down its losses sharply by 89% to Rs 5 crore in FY25 from Rs 45 crore in FY24. The firm posted positive EBITDA of Rs 32 crore in FY25 with EBITDA margin of 12.17%. Its ROCE stood at 2.73% in the same period. On a unit basis, the company spent Rs 1.05 to earn a rupee of operating revenue in FY25. The firmโ€™s current assets increased slightly to Rs 170 crore including cash and bank balances worth Rs 49 crore in the fiscal. According to startup data intelligence platform TheKredible, Healthians has raised a total of $75 million of funding till date, having WestBridge, BEENEXT, DG Ventures and Youwecan as its lead investors. The companyโ€™s founder and CEO, Deepak Sahni owns 6.5% of the company.

Related News

Healthians achieves EBITDA breakeven with Rs 250 Cr income in FY24

EntrackrEntrackr ยท 1y ago
Healthians achieves EBITDA breakeven with Rs 250 Cr income in FY24
Medial

Diagnostic startup Healthians recorded a modest 8% year-on-year growth during the fiscal year ending March 2024. However, the WestBridge-backed company reduced its losses by 65% and achieved EBITDA breakeven in the same period. Healthiansโ€™s revenue from operations increased to Rs 243 crore in FY24 from Rs 224 crore in FY23, its consolidated annual results sourced from the Ministry of Corporate Affairs (MCA) show. Healthians offers at-home diagnostic services across over 250 cities and claims to have conducted more than 10 crore tests to date. Income from running laboratories for pathological tests was the primary source of revenue for Healthians which increased 8.62% to Rs 240.5 crore in FY24. The rest of the collections were from the sale of supplements, which stood at Rs 2.2 crore in the last fiscal year. Healthians also added Rs 10 crore from non-operational activities (interest income) which tallied the overall revenue to Rs 253 crore in FY24, as compared to Rs 236 crore in FY23. The Gurugram-based company allocated 40% of its overall burn to employee benefits. This cost dropped by 11.8% to Rs 120 crore in FY24 compared to Rs 136 crore in FY23. Advertising expenses also shrank over 62% to Rs 39 crore in FY24 from Rs 103 crore in FY23. The cost of material consumed, rent, Information technology, and other overheads took the overall expenditure to Rs 298 crore in FY24. The controlled spending on advertising and employee benefits helped Healthians to narrow losses by 65% to Rs 45 crore in FY24. With this, the company has achieved EBITDA breakeven in the previous fiscal (FY24). Coming to the ratios, Healthiansโ€™ ROCE and EBITDA margins improved to -20.4% and 0% (breakeven) in FY24. It spent Rs 1.23 to earn a rupee in FY24. The company has a total current assets of Rs 62 crore including the cash and bank balances of Rs 30 crore in the previous fiscal. Healthians has raised around $80 million to date including its last round of $54 million led by WestBridge in 2022. According to the startup data intelligence platform TheKredible, WestBridge is the largest external stakeholder with 25% followed by Beenext and DG Ventures. Financial stability is the primary thing that a company needs to survive. It seems like Healthians got some of the mantras to how to be constant with the scale while burning low. Achieving EBITDA breakeven for the first time will give more confidence to both founders and investors. Turning this achievement into net profits is difficult yet achievable- an approach Dr. PathLabs has been executing for many years. The next two to three years will be crucial in shaping the company's trajectory.

Healthkartโ€™s revenue nears Rs 1,400 Cr in FY25; profit triples

EntrackrEntrackr ยท 11d ago
Healthkartโ€™s revenue nears Rs 1,400 Cr in FY25; profit triples
Medial

Healthkartโ€™s revenue nears Rs 1,400 Cr in FY25; profit triples HealthKart, a nutrition and supplement e-commerce platform, recorded a 3X year-on-year jump in profit after turning profitable in FY24. The Gurugram-based companyโ€™s sharp profit growth was steered by strong sales momentum and a controlled cost structure. Healthkartโ€™s operating revenue grew 29% to Rs 1,313 crore in FY25 from Rs 1,021 crore in FY24, according to its consolidated financial statement sourced from the Registrar of Companies (RoC). HealthKart owns and manufactures eight nutritional brands including popular supplement brands like MuscleBlaze, The Protein Zone, TrueBasics, HKVitals, bGreen, Nouriza, and Gritzo. Sales of products formed 97% of total revenue which rose by 29% to Rs 1,277 crore in FY25. Collections from services also increased by 16% to Rs 36 crore. Notably, non-operating revenue increased to Rs 55 crore in the last fiscal year from Rs 48 crore in FY24. The cost of materials accounted for the largest share of the companyโ€™s expenditure at 49%. To the tune of scale, this cost rose 26% to Rs 623 crore in FY25 from Rs 495 crore in FY25. Advertising spend saw a sharper rise of 39% to Rs 263 crore, while commission expenses increased 22% to Rs 82 crore. In contrast, employee benefit costs declined 5% to Rs 115 crore. Overall, Healthkart managed to keep its cost growth below revenue expansion. Its total expenses rose 23% to Rs 1,273 crore in FY25 from Rs 1,032 crore in FY24. The companyโ€™s profit surged over 3X to Rs 120 crore in FY25, while its ROCE and EBITDA margin improved to 5.45% and 6.02%, respectively. On a unit basis, Healthkart spent Re 0.97 to earn a rupee of operating revenue in FY25, compared to Rs 1.01 in FY24. As of FY25, its current assets stood at Rs 971 crore including Rs 73 crore in cash and bank balances. According to startup data intelligence platform TheKredible, Healthkart has raised a total of $382 million of funding till date, having Peak XV Partners, Temasek and Sofina as its lead investors. The companyโ€™s founder and CEO, Sameer Maheshwari owns 12% of the company.

Healthians posts Rs 224 Cr revenue and Rs 184 Cr loss in FY23

EntrackrEntrackr ยท 1y ago
Healthians posts Rs 224 Cr revenue and Rs 184 Cr loss in FY23
Medial

Healthtech startup Healthians had targeted Rs 500 crore revenue with profits in FY23. But it seems like the company has missed this projection by a significant margin: it did not reach even the halfway mark. At the same time, its losses spiked 55%. The companyโ€™s revenue from operations increased 34.13% to Rs 224 crore in FY23 from Rs 167 crore in FY22, its consolidated financial statements filed with the Registrar of Companies show. Healthians delivers health test at-home services, extending a diverse array of health tests across 250 cities in India. According to its website, the firm has facilitated over 100 million tests since its inception in 2015. The sale of diagnostics services was the primary source of revenue for Heathians while the rest of the income came from the sale of supplements. Visit TheKredible for a detailed revenue breakup. In line with similar healthtech platforms, its employee benefits formed 32% of the overall expenditure. This cost rose by 83.8% to Rs 136 crore in FY23 from Rs 74 crore in FY22. Its advertising and promotional costs also saw an increase of 45% in FY23. The cost of materials, legal-professional, technical service, information technology, and other overheads propelled its overall expenditure by 40.9% to Rs 420 crore in FY23 from Rs 298 crore in FY22. Head to TheKredible for a complete expense breakup. Expenses Breakdown Total โ‚น 298 Cr https://thekredible.com/company/healthians/financials View Full Data To access complete data, visithttps://thekredible.com/company/healthians/financials Total โ‚น 420 Cr https://thekredible.com/company/healthians/financials View Full Data To access complete data, visithttps://thekredible.com/company/healthians/financials Cost of materials consumed Cost of materials consumed Employee benefit Employee benefit Information technology Information technology Legal professional Legal professional Advertising promotional Advertising promotional Cost technical services Cost technical services Others To check complete Expense Breakdown visit thekredible.com View full data Caveat: We have excluded the gain/loss of the FVTPL for both years (FY23 and FY22). With the increase in expenses outpacing the revenue growth, losses for Healthians grew 54.6% to Rs 184 crore in FY23. Its ROCE and EBITDA stood at -74% and -61.4% respectively. FY22-FY23 FY22 FY23 EBITDA Margin -56% -61.4% Expense/โ‚น of Op Revenue โ‚น1.78 โ‚น1.88 ROCE -27% -74% On a unit level, it spent Rs 1.88 to earn a rupee in FY23. With the Covid pandemic and its associated after effects well behind now, itโ€™s a testing time in more ways than one for health test firms. So much so that larger diagnostic firms stopped providing splits between Covid and non-Covid testing some time ago. Established players are fighting back with a vengeance, even as customers seek more options. Hospital chains in the larger cities are also probably much more aggressive today in trying to retain their OPD business for their diagnostic clinics. As independent entities, Healthians faces the obvious issue of doctors not really recommending it or worse, discounting its test results, as we have observed in many cases. Add to that the intense competition and consequent discounting in the market today, and profits are the last thing on the mind of players. While a listed player like Dr Lal PathLabs might be more careful, others are not so worried as these seek to grab market share. More importantly, the larger players with a captive base like hospitals or even listed players have the money to invest in newer testing methods and technology. The next big market by all measures remains tier 3 and 4 cities, something that will not please Healthians again for the investments they will demand to set up a network. It is probably time to brainstorm around a clear differentiator in terms of communications, or even a test area it can count on for higher margins, for Healthians to make the next step towards sustainability.

Ixigo posts Rs 284 Cr revenue Q4 FY25; profit jumps 2.4X

EntrackrEntrackr ยท 6m ago
Ixigo posts Rs 284 Cr revenue Q4 FY25; profit jumps 2.4X
Medial

Ixigo released its financial results for the fourth quarter of the ongoing fiscal year (Q4 FY25) on Wednesday. The company reported a 72% growth in scale, while its year-on-year (YoY) profits increased by 2.4X during the same period. Ixigoโ€™s revenue from operations surged 72% to Rs 284 crore in Q4 FY25 in contrast to Rs 165 crore in Q4 FY24, as per the firmโ€™s consolidated financial results sourced from the National Stock Exchange (NSE). For the full fiscal year (FY25), Ixigoโ€™s operating revenue increased 39% to Rs 914 crore in FY25 from Rs 656 crore in FY24. The Gurugram-based company generated the largest share (44%) of its operating revenue from train ticketing, which rose to Rs 124 crore in Q4 FY25 from Rs 94 crore in Q4 FY24. Flight and bus booking services contributed 30% and 23% to the companyโ€™s revenue, respectively. According to the company, its gross transaction value (GTV) grew 65% year-on-year to Rs 4,418 crore in the fourth quarter of FY25, as compared to Rs 2,685 crore in the same quarter of the previous year. Besides operating revenue, the firm also earned Rs 6 crore via interest and gains from financial assets during the quarter which took its total topline to Rs 290 crore in the quarter ending March 2025. Ixigo has not provided a detailed breakdown of expenses in its quarterly financial statements. However, employee benefits expenses rose by 31% YoY to Rs 46 crore. Overall, the company's total costs grew 73% to Rs 263 crore in Q4 FY25 compared to Rs 152 crore in Q4 FY24. For the full financial year ending March 2025, the firmโ€™s total expenses rose to Rs 846 crore as against Rs 628 crore in FY24. In the end, Ixigo's net profits surged 2.4X to Rs 17 crore in Q4 FY25 from Rs 7 crore in Q4 FY24. On a fiscal basis, its net profit decreased 18% to Rs 60 crore in FY25 from Rs 73 crore in FY24. Ixigo is currently trading at Rs 167 at the end of todayโ€™s session with a total market capitalization of Rs 6,500 crore (approximately $760 million).

Redcliffe Labs posts Rs 419 Cr revenue in FY25; narrows EBITDA losses

EntrackrEntrackr ยท 4m ago
Redcliffe Labs posts Rs 419 Cr revenue in FY25; narrows EBITDA losses
Medial

Redcliffe Labs posts Rs 419 Cr revenue in FY25; narrows EBITDA losses Diagnostics platform Redcliffe Labs has posted a 20% increase in its operating revenue to Rs 419 crore in FY25 from Rs 350 crore in FY24 and managed to narrow its EBITDA losses, as per the companyโ€™s press release. Diagnostics platform Redcliffe Labs has posted a 20% increase in its operating revenue to Rs 419 crore in FY25 from Rs 350 crore in FY24, as per the companyโ€™s press release. The Gurugram-based firm also managed to reduce its EBITDA losses from -38% to -21% during the same period. Founded by Aditya Kandoi, Redcliffe operates a nationwide network of over 80 labs and claims to have the widest home sample collection footprint in the country. Diagnostic services contributed over 95% of the companyโ€™s revenue in FY25, with the rest coming from product sales and other operating income. The company said it diagnosed over 2.5 million cases last fiscal and continues to focus on expanding in underserved regions, with more than 70% of its testing volumes now coming from Tier II cities and beyond. On the profitability front, Redcliffe reported a gross margin of 70% in FY25 and is aiming to expand it to 74% in FY26. It has also set a revenue target of Rs 560 crore for the ongoing fiscal through organic growth and strategic acquisitions. โ€œWe are transforming lives and making diagnostics a first-line solution for millions who were previously underserved,โ€ said Kandoi. The company plans to expand its presence to over 300 cities with 150 labs by FY28. According to startup data platform TheKredible, Redcliffe has raised $113 million to date, including a $42 million Series C round led by LeapFrog. It also acquired Bengaluru-based Celara Diagnostics in a $7 million deal. Redcliffe competes with players like PharmEasy-owned Thyrocare, Tata 1mg, and Healthians.

Gameskraft crosses Rs 4,000 Cr revenue in FY25; PAT nears Rs 1,000 Cr

EntrackrEntrackr ยท 2m ago
Gameskraft crosses Rs 4,000 Cr revenue in FY25; PAT nears Rs 1,000 Cr
Medial

Gameskraft crosses Rs 4,000 Cr revenue in FY25; PAT nears Rs 1,000 Cr Gameskraftโ€™s FY25 numbers reflect strong performance before the RMG ban. The firm reported double-digit revenue growth and maintained profitability during the fiscal year. The Indian governmentโ€™s recent ban on real-money gaming formats has disrupted the sector overnight, but Gameskraftโ€™s FY25 numbers reflect strong performance before the clampdown. The firm reported double-digit revenue growth and maintained profitability during the fiscal year. Gameskraftโ€™s revenue from operations grew 12% to Rs 3,896 crore in FY25 from Rs 3,475 crore in FY24, according to its consolidated financial statements sourced from the Registrar of Companies (RoC). Gameskraft operated popular gaming apps such as Rummy Culture, Playship, Pocket 52, RummyPrime, Ludo Culture, and Rummy Time. Its revenue (gross gaming revenue) came from platform fee or commission charged as a percentage of the buy-in fees users invest in games, which contributed Rs 3,882 crore (99.6% of operating revenue), registering a 12.2% growth. Its real estate business added Rs 11 crore, while other income sources contributed Rs 3 crore in FY25. The Bengaluru-based company made an additional Rs 113 crore from non-operating sources which pushed its total revenue to Rs 4,009 crore in FY25. On the cost side, promotional spending emerged as the single largest expense and accounted for 75% of total burn. To the tune of scale, this cost surged 58% to Rs 2,072 crore in FY25 from Rs 1,315 crore in FY24. Employee benefits, on the other hand, saw a decline of 11% to Rs 410 crore, while legal and professional fees fell 22.8% to Rs 112 crore in FY25. Overall, the companyโ€™s total expenses shot up 24% to Rs 2,766 crore in FY25 as against Rs 2,232 crore in FY24. See TheKredible for the detailed cost breakdown during the last fiscal year. Despite the jump in ad spend, Gameskraft managed to sustain profitability on the back of its strong topline and controlled costs in other areas. Its net profit stood at Rs 976 crore in FY25, slightly higher than the Rs 947 crore posted in FY24. It's worth noting that we have excluded exceptional items worth Rs 270.5 crore in the calculation of net profit of the company. Gameskraft's ROCE and EBITDA margin stood at 58.40% and 31.63%, respectively. On a unit basis, Gameskraft spent Rs 0.71 to earn a rupee of operating revenue in FY25. The company recorded current assets worth Rs 2,232 crore in FY25 which includes Rs 253 crore in cash and bank balances and Rs 1,319 crore invested in mutual funds. While Gameskraftโ€™s FY25 numbers were unaffected, the Indian governmentโ€™s new gaming law effective August 2025 has forced the company to halt its real-money operations, including shutting down โ€œAdd Cashโ€ features and discontinuing its flagship rummy platform RummyCulture, alongside pausing its poker venture Pocket52 earlier in the year. The move, mandated by the Promotion and Regulation of Online Gaming Act, has also led Gameskraft to publicly state it will not pursue a legal challenge, instead opting for full compliance. Given that real-money gaming contributed nearly all of Gameskraftโ€™s FY25 revenue, the ban is expected to significantly impact its business model, revenue streams, and growth trajectory going forward.

Paytm posts Rs 1,828 Cr revenue and Rs 208 Cr loss in Q3 FY25

EntrackrEntrackr ยท 10m ago
Paytm posts Rs 1,828 Cr revenue and Rs 208 Cr loss in Q3 FY25
Medial

Fintech firm Paytm announced its financial results for the third quarter of the current fiscal year (Q3 FY25) on Monday. The Noida-based company reported revenue of Rs 1,828 crore and a net loss of Rs 208 crore for the period. According to Paytmโ€™s unaudited consolidated quarterly report filed with the National Stock Exchange, its revenue from operations declined by 35.9% year-on-year from Rs 2,850 crore in Q3 FY24 to Rs 1,828 crore in Q3 FY25. However, on a quarter-on-quarter basis, the firm recorded a 10% increase in revenue compared to Q2 FY25 (the preceding quarter). Income from payment service revenue accounted for 55% of the total operating revenue which stood at Rs 1,003 crore in Q3 FY25 while the revenue from financial and marketing services were recorded at Rs 502 crore and Rs 267 crore in the same period. The company also added Rs 189 crore from other non-operating sources, bringing its overall revenue to Rs 2016.5 crore in Q3 FY25. For the fintech firm, its employee benefits remained the largest cost center accounting for 34% of the overall cost which decreased by 36% to Rs 756 crore in Q3 FY25. This includes Rs 182 crore as ESOP cost (non-cash). Its payment processing charges and marketing costs were reduced by 42% and 48.7% to Rs 570 crore and Rs 141 crore respectively in Q3 FY25 from Rs 982 crore and Rs 275 crore in Q3 FY24. Software, communication, legal, cashback, and other overheads took the total expenditure to Rs 2,220 crore in Q3 FY25 from Rs 3,216 crore in Q3 FY24. A reduction across all overhead departments enabled Paytm to narrow its losses by 6.3% to Rs 208 crore in Q3 FY25 from Rs 222 crore in Q3 FY24.

Nazara posts Rs 520 Cr revenue and Rs 4 Cr PAT in Q4 FY25

EntrackrEntrackr ยท 6m ago
Nazara posts Rs 520 Cr revenue and Rs 4 Cr PAT in Q4 FY25
Medial

Nazara posts Rs 520 Cr revenue and Rs 4 Cr PAT in Q4 FY25 Gaming and sports media firm Nazara Technologies reported a 95% year-on-year rise in operating revenue for Q4 FY25. However, the Mumbai-based companyโ€™s profit remained modest at Rs 4 crore in the final quarter of the previous fiscal year. Nazaraโ€™s operating revenue rose by 95.3% to Rs 520 crore in Q4 FY25 from Rs 266 crore in Q4 FY24, according to its audited consolidated financial statements sourced from the National Stock Exchange (NSE). E-sports accounted for 41.5% (Rs 216 crore) of the companyโ€™s total operating revenue, while the gaming segment held a 30% share (Rs 156 crore), followed by ad tech, which contributed 28% (Rs 148 crore). Nazara also earned Rs 18 crore from interest and gains on financial assets during the quarter, bringing its overall revenue to Rs 539 crore. However, the company posted a 40.8% YoY increase in its total income to Rs 1,715 crore in FY25, compared to Rs 1,218 crore in FY24. On the line of scale, Nazaraโ€™s total expenses surged by 85.3% to Rs 528 crore in Q4 FY25, compared to Rs 285 crore in the same quarter last year. Content and commission costs together stood at Rs 186 crore, while employee benefit expenses rose to Rs 80 crore. Notably, marketing expenses saw a sharp 3.5X jump, reaching Rs 151 crore in Q4 FY25. Despite a 95% year-on-year revenue growth in Q4, the companyโ€™s profit remained flat at Rs 4 crore in Q4 FY25. For the full fiscal year, its net profit declined to Rs 51 crore in FY25 from Rs 74.7 crore in FY24. Last week, the Competition Commission of India (CCI) also approved the acquisition of a majority stake and control over Nazara Technologies Limited by Axana Estates LLP, Plutus Wealth Management LLP, and Junomoneta Finsol Private Limited. Nazara is currently trading at Rs 1,270 (as of 03.41 PM) with a total market capitalization of Rs 11,127 crore (approximately $1.3 billion).

Tata 1mg revenue nears Rs 2,400 Cr in FY25, trims losses

EntrackrEntrackr ยท 4m ago
Tata 1mg revenue nears Rs 2,400 Cr in FY25, trims losses
Medial

Tata 1mg, the digital healthcare platform backed by Tata Digital, continued its growth trajectory in the fiscal year ending March 2025 while straining its losses. Tata 1mgโ€™s consolidated revenue rose 22% to Rs 2,392 crore in FY25 from Rs 1,968 crore in FY24, according to Tata Sonsโ€™ Annual Report for the fiscal year. Tata 1mg is a health tech startup for online orders of allopathic, ayurvedic, homeopathic medicines, vitamins, nutrition supplements, and other health products, delivered to the home. 1mgโ€™s revenue was split across two entities: Tata 1mg Technologies, which clocked Rs 2,016.5 crore, and Tata 1mg Healthcare Solutions, which contributed Rs 375.5 crore in FY25. The company's total cost rose by 17% to Rs 2682 crore in FY25, up from Rs 2303 crore in FY24. The Gurugram-based company posted a consolidated loss of Rs 276 crore in FY25, 12% lower than the Rs 313 crore loss reported in FY24. On a unit basis, the company spent Rs 1.12 to earn a rupee of operating revenue in FY25. On the asset side, Tata 1mg reported total assets of Rs 2,025 crore at the end of FY25 while its total liabilities reached Rs 1,190 crore. In the e-health space, Tata 1mg competes with Reliance-backed Netmeds, PharmEasy, and Apollo 24/7. Tata Digital acquired a 55% stake in 1mg in June 2021 but has since gained around 8.5% additional stake in the e-medicine platform. According to TheKredible, Tata Digital currently holds a 63.5% stake in 1mg, which was last valued at 1.25 billion. Tata Digital reported a standalone revenue of Rs 546.9 crore and a loss of Rs 827.5 crore in FY25, indicating continued investment in its digital commerce bets including 1mg and other verticals such as BigBasket, Cult.fit, and the recently launched Tata Neu.

MapMyIndia posts Rs 140 Cr revenue in Q4 FY25, profit grows 29%

EntrackrEntrackr ยท 6m ago
MapMyIndia posts Rs 140 Cr revenue in Q4 FY25, profit grows 29%
Medial

MapMyIndia posts Rs 140 Cr revenue in Q4 FY25, profit grows 29% CE Info Systems, the parent company of MapMyIndia, has announced its financial results for the fourth quarter of FY25. The company reported a year-on-year revenue growth of over 34% compared to Q4 FY24. MapMyIndiaโ€™s revenue from operations increased to Rs 143 crore in Q4 FY25 from Rs 107 crore in Q4 FY24. Meanwhile, for the full fiscal year, revenue increased by 22% to Rs 463 crore in FY25 from Rs 379 crore in FY24, according to its consolidated quarterly report. Income from digital map data, GPS navigation, location-based services, and IoT was the primary source of revenue for MapMyIndia, accounting for 88% of the total collection. This revenue source increased by 51% to Rs 127 crore in Q4 FY25. However, income from the sale of its devices generated Rs 16.5 crore in revenue. The cost of IoT devices, employee benefits, and outsourced technical services were the major cost elements, pushing the total cost of the firm to Rs 90 crore in Q4 FY25, up from Rs 72 crore in Q4 FY24. On a fiscal basis, the total cost increased to Rs 306 crore in FY25. With the increase in scale, MapMyIndia recorded a 29% increase in its profit to Rs 49 crore during Q4 FY25, compared to Rs 38 crore in the fourth quarter of the previous fiscal year. Meanwhile, annual profit increased by 10% to Rs 148 crore in FY25, up from Rs 134 crore in FY24. At the end of the day on 9th May 2025, MapMyIndia closed at Rs 1,845 per share, with a market capitalization of Rs 10,040 crore ($1.17 billion).

Download the medial app to read full posts, comements and news.